Unknown

Dataset Information

0

A cross-sectional natural history study of aspartylglucosaminuria.


ABSTRACT: Aspartylglucosaminuria (AGU) is a rare lysosomal storage disorder that causes stagnation of development in adolescence and neurodegeneration in early adulthood. Precision therapies, including gene transfer therapy, are in development with a goal of taking advantage of the slow clinical course. Understanding of disease natural history and identification of disease-relevant biomarkers are important steps in clinical trial readiness. We describe the clinical features of a diverse population of patients with AGU, including potential imaging and electrophysiological biomarkers. This is a single-center, cross-sectional study of the clinical, neuropsychological, electrophysiological, and imaging characteristics of AGU. A comprehensive assessment of eight participants (5 Non-Finnish) revealed a mean non-verbal IQ (NVIQ) of 70.25 ± 10.33 which decreased with age (rs = -0.85, p = 0.008). All participants demonstrated deficits in communication and gross/fine motor dysfunction. Auditory and visual evoked potentials demonstrated abnormalities in one or both modalities in 7 of 8 subjects, suggesting sensory pathway dysfunction. Brain imaging demonstrated T2 FLAIR hypointensity in the pulvinar nuclei and cerebral atrophy, as previously shown in the Finnish AGU population. Magnetic resonance spectroscopy (MRS) showed a 5.1 ppm peak corresponding to the toxic substrate (GlcNAc-Asn), which accumulates in AGU. Our results showed there was no significant difference between Finnish and Non-Finnish patients, and performance on standardized cognitive and motor testing was similar to prior studies. Age-related changes on functional assessments and disease-relevant abnormalities on surrogate biomarkers, such as MRS, could be used as outcome measures in a clinical trial.

SUBMITTER: Goodspeed K 

PROVIDER: S-EPMC9458605 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A cross-sectional natural history study of aspartylglucosaminuria.

Goodspeed Kimberly K   Horton Daniel D   Lowden Andrea A   Sguigna Peter V PV   Booth Timothy T   Wang Zhiyue J ZJ   Edgar Veronica Bordes VB  

JIMD reports 20220714 5


Aspartylglucosaminuria (AGU) is a rare lysosomal storage disorder that causes stagnation of development in adolescence and neurodegeneration in early adulthood. Precision therapies, including gene transfer therapy, are in development with a goal of taking advantage of the slow clinical course. Understanding of disease natural history and identification of disease-relevant biomarkers are important steps in clinical trial readiness. We describe the clinical features of a diverse population of pati  ...[more]

Similar Datasets

| S-EPMC5319901 | biostudies-literature
| S-EPMC7733183 | biostudies-literature
| S-EPMC8634068 | biostudies-literature
2018-11-25 | GSE121633 | GEO
| S-EPMC6499994 | biostudies-literature
| S-EPMC3209435 | biostudies-literature
| S-EPMC7935713 | biostudies-literature
| S-EPMC11616230 | biostudies-literature
2023-09-01 | GSE236927 | GEO
2023-10-24 | GSE207748 | GEO